Cell-Model Findings and Cognitive Symptoms

Cognitive complaints can arise in many different conditions. Similar words such as “brain fog” do not establish a shared cause, much less a shared response to electrical stimulation. Mechanisms and clinical management need to be assessed within each diagnosis.

A preclinical observation

Merighi and colleagues studied 75 Hz PEMF in cultured neuronal and microglial cell lines challenged with amyloid-β, hydrogen peroxide or LPS. Their endpoints included oxidative stress, mitochondria and cell death. This is cell-model evidence. It does not show improvement in memory or fatigue in people, or any effect in long COVID, Lyme disease or chemotherapy-associated cognitive symptoms.

What translation would require

Investigators would have to ask whether the cell-model exposure is relevant to living tissue and whether the proposed mechanism appears in the particular patient group. Then a defined device could be compared against appropriate care using meaningful cognitive and functional endpoints and adverse-event monitoring. A sensor or algorithm would need separate validation before it could inform treatment adjustments.

Inflammatory mechanisms may be investigated in several diagnoses, but that is not evidence that neuroinflammation explains every patient's symptoms. The linked study is a narrow experimental starting point, not a treatment recommendation.

Separating cognitive conditions before testing stimulation Define the underlying condition

Measure relevant neuroinflammatory signals

Evaluate any stimulation approach within that condition

What the linked references do not establish: The cited PEMF findings concern amyloid-beta-injured cultured cells, not clinical outcomes for long COVID, Lyme disease, or brain fog.